Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer

AstraZeneca

Status and phase: Terminated; Phase 2

Conditions: Non Small Cell Lung Cancer; Brain Neoplasms

Treatments: Drug: Iressa (Gefitinib)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00234442

1839IL/0569

Details and patient eligibility

About

The aim of the study is to determine if Iressa is effective in the treatment of Brain metastases from NCSLC

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Radiologically confirmed brain metastases from Non Small Cell Lung Cancer
• No symptoms due to brain metastases
• No previous radiotherapy treatment for the Brain metastases

Exclusion criteria

• No prior chemotherapy
• No other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
• Any evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease)

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)